FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385985576> ?p ?o ?g. }

• W4385985576 abstract "Abstract Background Older primary central nervous system lymphoma (PCNSL) patients have an inferior prognosis compared to younger patients because available evidence on best treatment is scarce and treatment delivery is challenging due to comorbidities and reduced performance status. High-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT) after high-dose methotrexate (MTX)-based immuno-chemotherapy has become an increasingly used treatment approach in eligible elderly PCNSL patients with promising feasibility and efficacy, but has not been compared with conventional chemotherapy approaches. In addition, eligibility for HCT-ASCT in elderly PCNSL is not well defined. Geriatric assessment (GA) may be helpful in selecting patients for the best individual treatment choice, but no standardized GA exists to date. A randomized controlled trial, incorporating a GA and comparing age-adapted HCT-ASCT treatment with conventional chemotherapy is needed. Methods This open-label, multicenter, randomized phase III trial with two parallel arms will recruit 310 patients with newly diagnosed PCNSL > 65 years of age in 40 centers in Germany and Austria. The primary objective is to demonstrate that intensified chemotherapy followed by consolidating HCT-ASCT is superior to conventional chemotherapy with rituximab, MTX, procarbazine (R-MP) followed by maintenance with procarbazine in terms of progression free survival (PFS). Secondary endpoints include overall survival (OS), event free survival (EFS), (neuro-)toxicity and quality of life (QoL). GA will be conducted at specific time points during the course of the study. All patients will be treated with a pre-phase rituximab-MTX (R-MTX) cycle followed by re-assessment of transplant eligibility. Patients judged transplant eligible will be randomized (1:1). Patients in arm A will be treated with 3 cycles of R-MP followed by maintenance therapy with procarbazine for 6 months. Patients in arm B will be treated with 2 cycles of MARTA (R-MTX/AraC) followed by busulfan- and thiotepa-based HCT-ASCT. Discussion The best treatment strategy for elderly PCNSL patients remains unknown. Treatments range from palliative to curative but more toxic therapies, and there is no standardized measure to select patients for the right treatment. This randomized controlled trial will create evidence for the best treatment strategy with the focus on developing a standardized GA to help define eligibility for an intensive treatment approach. Trial registration German clinical trials registry DRKS00024085 registered March 29, 2023." @default.
• W4385985576 created "2023-08-19" @default.
• W4385985576 creator A5000276455 @default.
• W4385985576 creator A5007752109 @default.
• W4385985576 creator A5010948621 @default.
• W4385985576 creator A5018113411 @default.
• W4385985576 creator A5023417817 @default.
• W4385985576 creator A5031815102 @default.
• W4385985576 creator A5033105670 @default.
• W4385985576 creator A5033240118 @default.
• W4385985576 creator A5035666187 @default.
• W4385985576 creator A5041211009 @default.
• W4385985576 creator A5045194637 @default.
• W4385985576 creator A5048078190 @default.
• W4385985576 creator A5049307026 @default.
• W4385985576 creator A5054234375 @default.
• W4385985576 creator A5056785499 @default.
• W4385985576 creator A5057483013 @default.
• W4385985576 creator A5058654033 @default.
• W4385985576 creator A5058763790 @default.
• W4385985576 creator A5066153514 @default.
• W4385985576 creator A5071989499 @default.
• W4385985576 creator A5091896726 @default.
• W4385985576 creator A5092128813 @default.
• W4385985576 creator A5092493739 @default.
• W4385985576 creator A5092493740 @default.
• W4385985576 creator A5092493741 @default.
• W4385985576 creator A5003546165 @default.
• W4385985576 creator A5065626686 @default.
• W4385985576 date "2023-08-18" @default.
• W4385985576 modified "2023-10-13" @default.
• W4385985576 title "Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMA-CNS trial" @default.
• W4385985576 cites W1963543274 @default.
• W4385985576 cites W1988992782 @default.
• W4385985576 cites W2000445173 @default.
• W4385985576 cites W2018713883 @default.
• W4385985576 cites W2043705607 @default.
• W4385985576 cites W2065173279 @default.
• W4385985576 cites W2072044537 @default.
• W4385985576 cites W2108465006 @default.
• W4385985576 cites W2108686394 @default.
• W4385985576 cites W2111412973 @default.
• W4385985576 cites W2128529067 @default.
• W4385985576 cites W2136621779 @default.
• W4385985576 cites W2148309601 @default.
• W4385985576 cites W2149603266 @default.
• W4385985576 cites W2156402672 @default.
• W4385985576 cites W2160293835 @default.
• W4385985576 cites W2163181792 @default.
• W4385985576 cites W2164059021 @default.
• W4385985576 cites W2165758561 @default.
• W4385985576 cites W2167571044 @default.
• W4385985576 cites W2292827530 @default.
• W4385985576 cites W2313099741 @default.
• W4385985576 cites W2314481096 @default.
• W4385985576 cites W2556517183 @default.
• W4385985576 cites W2563063147 @default.
• W4385985576 cites W2608394083 @default.
• W4385985576 cites W2621307899 @default.
• W4385985576 cites W2731092161 @default.
• W4385985576 cites W2761111503 @default.
• W4385985576 cites W2766491362 @default.
• W4385985576 cites W2768689142 @default.
• W4385985576 cites W2791302770 @default.
• W4385985576 cites W2886729613 @default.
• W4385985576 cites W2914286716 @default.
• W4385985576 cites W2936481109 @default.
• W4385985576 cites W2997386338 @default.
• W4385985576 cites W3004116732 @default.
• W4385985576 cites W3046114750 @default.
• W4385985576 cites W3127059308 @default.
• W4385985576 cites W3193317429 @default.
• W4385985576 cites W3193728078 @default.
• W4385985576 cites W3207764260 @default.
• W4385985576 cites W4295117943 @default.
• W4385985576 cites W4310125682 @default.
• W4385985576 cites W4311165639 @default.
• W4385985576 cites W4312094681 @default.
• W4385985576 doi "https://doi.org/10.1186/s12885-023-11193-7" @default.
• W4385985576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37596517" @default.
• W4385985576 hasPublicationYear "2023" @default.
• W4385985576 type Work @default.
• W4385985576 citedByCount "1" @default.
• W4385985576 crossrefType "journal-article" @default.
• W4385985576 hasAuthorship W4385985576A5000276455 @default.
• W4385985576 hasAuthorship W4385985576A5003546165 @default.
• W4385985576 hasAuthorship W4385985576A5007752109 @default.
• W4385985576 hasAuthorship W4385985576A5010948621 @default.
• W4385985576 hasAuthorship W4385985576A5018113411 @default.
• W4385985576 hasAuthorship W4385985576A5023417817 @default.
• W4385985576 hasAuthorship W4385985576A5031815102 @default.
• W4385985576 hasAuthorship W4385985576A5033105670 @default.
• W4385985576 hasAuthorship W4385985576A5033240118 @default.
• W4385985576 hasAuthorship W4385985576A5035666187 @default.
• W4385985576 hasAuthorship W4385985576A5041211009 @default.
• W4385985576 hasAuthorship W4385985576A5045194637 @default.
• W4385985576 hasAuthorship W4385985576A5048078190 @default.
• W4385985576 hasAuthorship W4385985576A5049307026 @default.
• W4385985576 hasAuthorship W4385985576A5054234375 @default.
• W4385985576 hasAuthorship W4385985576A5056785499 @default.

• next